IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

NCT05970263 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Recruitment challenges

Conditions

COPD

Interventions

DRUG: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
OTHER: External Comparator

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]